Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

Study Elucidates How Mutant NPM1 Protein Drives Leukemia by Activating Autophagy System

In a recent study, scientists led by Professor Stefan Müller from Goethe University's Institute of Biochemistry II investigated a specific form of blood cancer known as acute myeloid leukemia, or AML.

5 Dec 2023

Wilmot Researchers Uncover a "Genomic Tug of War" That Influences Decitabine's Effectiveness

Some patients with myelodysplastic syndromes, like acute myeloid leukemia, benefit from a chemotherapy drug called decitabine that stunts cancer growth. But many others are resistant to decatibine's effects or become resistant over time.

17 Nov 2023

Mechanisms of MCL-1 Inhibitor-Induced MCL-1 Protein Upregulation and Induction of Apoptosis

A new editorial paper was published in Oncotarget's Volume 14 on June 21, 2023, entitled, "Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability."

29 Jun 2023

Cell Fate Conversion Plays Crucial Role in Cancer Research

Researchers from the Max Delbrück Center for Molecular Medicine in the Helmholtz Association in Berlin and the Centre for Genomic Regulation (CRG) in Barcelona have discovered how cells speed changes to their identity known as “cell fate conversion.”

28 Jun 2023

CloneTracer Reveals a Differentiation Landscape of Acute Myeloid Leukemia

Researchers have developed a new method to distinguish between cancerous and healthy stem cells and progenitor cells from samples of patients with acute myeloid leukemia (AML), a disease driven by malignant blood stem cells that have historically been difficult to identify.

25 Apr 2023

New Epigenetic Vulnerability Of Acute Myeloid Leukemia Revealed

Acute myeloid leukemia (AML) is an aggressive blood cancer that causes uncontrolled accumulation of white blood cells. Because of the poor outcomes of this disease, researchers across the globe have been on the hunt for new ways to treat AML, while preserving normal blood development.

10 Apr 2023

Previously unknown telomere and cancer connection to the immune system revealed

Johns Hopkins Medicine scientists say their 20-year study of more than 200 people with premature aging syndromes caused by abnormally short telomeres, or shortened repetitive DNA sequences at the ends of chromosomes, may upend long-held scientific dogma and settle conflicting studies about how and whether short telomeres contribute to cancer risk.

31 Mar 2023

Potential therapeutic can synergize with existing drugs to effectively destroy leukemia cells

A team of researchers has discovered a potential therapeutic that can synergize with existing drugs to more effectively kill certain leukemia cells.

9 Mar 2023

Study pinpoints a splicing deregulation that causes therapeutic vulnerability in pediatric AML

Pediatric acute myeloid leukemia or pAML is a childhood blood cancer, one that has proved confounding to clinicians and researchers, with a high relapse rate and relatively few identified genetic mutations (compared to the adult version) that might explain its cause.

8 Mar 2023

Reversal of ADAR1 hyper-editing with small molecule inhibitor

Researchers at University of California San Diego School of Medicine, Sanford Stem Cell Institute and Moores Cancer Center report that a late-stage, pre-clinical small molecule inhibitor, called rebecsinib, reverses malignant hyper-editing by an inflammation-induced protein isoform, known as ADAR1 p150.

17 Feb 2023

Novel combination therapy shows promise in acute myeloid leukemia

Acute myeloid leukemia (AML) is an aggressive form of cancer that originates in the bone marrow, rapidly spreads to the blood and can quickly cause death if not treated promptly.

8 Feb 2023

Revealing the functional significance of DDX41 in great detail

The DDX41 gene encodes the nuclear enzyme DEAD-box-type RNA helicase. Hematopoietic malignancies are caused by DDX41 mutations. However, the mechanism behind the development of this malignancy remains unknown.

21 Nov 2022

Spaceflight increases the risk of developing cancer and heart disease

A groundbreaking study from the Icahn School of Medicine at Mount Sinai found that astronauts are more likely to experience mutations that could be connected to spaceflight and increase their lifetime risk of acquiring cancer and heart disease.

2 Sep 2022

Rewiring the inner workings of leukemia cells to reverse drug resistance

Researchers from Barts Cancer Institute at Queen Mary University of London have identified a way to reverse resistance to a group of cancer drugs, known as kinase inhibitors, in leukemia cells.

20 Apr 2022

Study highlights the role of genetic “bridge” in leukemia development

A complex network of three-dimensional structures assembles to read, copy and produce the genetic materials required for cellular function, for cells to thrive.

From Penn State University 14 Mar 2022

Two distinct classes of stem cells drive treatment resistance in patients with myelodysplastic syndromes

Researchers from The University of Texas MD Anderson Cancer Center discovered that treatment resistance in patients with myelodysplastic syndromes (MDS) is caused by two distinct classes of stem cells and identified possible therapeutic approaches that target these cells.

3 Mar 2022

Acute Myeloid Leukemia News and Research

Study Elucidates How Mutant NPM1 Protein Drives Leukemia by Activating Autophagy System

Wilmot Researchers Uncover a "Genomic Tug of War" That Influences Decitabine's Effectiveness

Mechanisms of MCL-1 Inhibitor-Induced MCL-1 Protein Upregulation and Induction of Apoptosis

Cell Fate Conversion Plays Crucial Role in Cancer Research

CloneTracer Reveals a Differentiation Landscape of Acute Myeloid Leukemia

New Epigenetic Vulnerability Of Acute Myeloid Leukemia Revealed

Previously unknown telomere and cancer connection to the immune system revealed

Potential therapeutic can synergize with existing drugs to effectively destroy leukemia cells

Study pinpoints a splicing deregulation that causes therapeutic vulnerability in pediatric AML

Reversal of ADAR1 hyper-editing with small molecule inhibitor

Novel combination therapy shows promise in acute myeloid leukemia

Revealing the functional significance of DDX41 in great detail

Spaceflight increases the risk of developing cancer and heart disease

Rewiring the inner workings of leukemia cells to reverse drug resistance

Study highlights the role of genetic “bridge” in leukemia development

Two distinct classes of stem cells drive treatment resistance in patients with myelodysplastic syndromes

Experts trigger apoptosis in leukemia cells by disrupting their energy maintenance mechanism

New proteomics method identifies proteins responsible for regulating R-loop levels in human cells

CSHL researchers spotlight the role of a previously little-known protein in leukemia

Researchers identify a new approach to triggering differentiation in acute myeloid leukemia

Quorum Bio: Where Synthetic Biology Meets Sustainable Farming

Diagnostic Biochips: Pioneering Brain Research Tools for the Future

Commercializing Innovation in a Life Sciences Ecosystem

Latest in Genomics